Caribou Biosciences Inc (CRBU) Stock Price, Quote & News

Latest News on CRBU

Apr 3, 2025, 10:00 AM EDT - 10 hours ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 2 days ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 30, 2025, 10:00 AM EDT - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect

Mar 27, 2025, 10:00 AM EDT - 7 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation

Mar 25, 2025, 10:00 AM EDT - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation

Mar 20, 2025, 10:00 AM EDT - 14 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out

Mar 18, 2025, 10:00 AM EDT - 16 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect

Mar 16, 2025, 10:00 AM EDT - 18 days ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 13, 2025, 10:00 AM EDT - 21 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation

Mar 11, 2025, 10:00 AM EDT - 23 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation

Mar 10, 2025, 4:05 PM EDT - 24 days ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 5:45 AM EST - 5 weeks ago

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Feb 23, 2025, 9:27 AM EST - 5 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 20, 2025, 1:28 PM EST - 6 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

Feb 19, 2025, 10:22 AM EST - 6 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 18, 2025, 4:05 PM EST - 6 weeks ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

Feb 15, 2025, 3:04 PM EST - 6 weeks ago

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

Jan 29, 2025, 10:51 AM EST - 2 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Jan 12, 2025, 7:05 PM EST - 2 months ago

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

Jan 7, 2025, 4:00 PM EST - 3 months ago

Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 26, 2024, 6:23 PM EST - 3 months ago

Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

Sep 30, 2024, 3:53 AM EDT - 6 months ago

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Aug 12, 2024, 8:00 AM EDT - 8 months ago

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

Jul 9, 2024, 8:00 AM EDT - 9 months ago

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

Jul 3, 2024, 3:11 AM EDT - 9 months ago

Market Cap	78.23M
Revenue (ttm)	9.99M
Net Income (ttm)	-149.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,492.59%
Debt to Equity Ratio	0.00

Volume	953,700
Avg Vol	1,152,454
Day's Range	N/A - N/A
Shares Out	93.01M
Stochastic %K	41%
Beta	2.36
Analysts	Strong Sell
Price Target	$12.00